Topics:
hematopoietic stem cell transplantation, leukemia, myelocytic, acute, misconceptions

On page 2309 in the 24 February 2011 issue, there is an error in Figure 1; panel 1A and B are reversed. The corrected Figure 1 is shown.

Figure 1
Figure 1. Trends in allogeneic HCT activity in adult AML patients (≥ 18 years) by the use of unrelated donors according to disease status at HCT: cases registered with CIBMTR from 1998 to 2008. (A) Adult AML patients (≥ 18 years), CR1, CR2, CR3, and not in remission, undergoing unrelated HCT. (B) Adult AML patients (≥ 18 years) undergoing unrelated HCT in CR1.
View largeDownload PPT

Trends in allogeneic HCT activity in adult AML patients (≥ 18 years) by the use of unrelated donors according to disease status at HCT: cases registered with CIBMTR from 1998 to 2008. (A) Adult AML patients (≥ 18 years), CR1, CR2, CR3, and not in remission, undergoing unrelated HCT. (B) Adult AML patients (≥ 18 years) undergoing unrelated HCT in CR1.

Figure 1
Figure 1. Trends in allogeneic HCT activity in adult AML patients (≥ 18 years) by the use of unrelated donors according to disease status at HCT: cases registered with CIBMTR from 1998 to 2008. (A) Adult AML patients (≥ 18 years), CR1, CR2, CR3, and not in remission, undergoing unrelated HCT. (B) Adult AML patients (≥ 18 years) undergoing unrelated HCT in CR1.
View largeDownload PPT

Trends in allogeneic HCT activity in adult AML patients (≥ 18 years) by the use of unrelated donors according to disease status at HCT: cases registered with CIBMTR from 1998 to 2008. (A) Adult AML patients (≥ 18 years), CR1, CR2, CR3, and not in remission, undergoing unrelated HCT. (B) Adult AML patients (≥ 18 years) undergoing unrelated HCT in CR1.

Close modal
© 2012 by The American Society of Hematology
2012
Sign in via your Institution